PEGylated Drugs Market Research Report - Global Forecast till 2027

PEGylated Drugs Market: Information by Molecule (Protein, FAB’ Fragment, Enzyme and Aptamer), by Indication (Cancer, Gout, Hemophilia and Hepatitis) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/6964-CR | October 2019 | Region: Global | 103 Pages         

PEGylated Drugs Market Speak to Analyst Request a Free Sample

PEGylated Drugs Market Overview

based on the studies, the pegylated drugs market is expected to witness a market growth at a CAGR of 5.53% during the forecast period. By the end of 2025, the PEGylated Drugs Market is expected to reach a revenue of USD 13.5 billion. Pegylated is the attachment process of covalent and non-covalent glycol polymer chains with bioactive molecules such as peptides, proteins, antibody fragments, enzymes and oligonucleotides etc.  It is safe technique that is used in increasing the therapeutic efficiency of medicines in a clinical atmosphere. There are many fda approved pegylated drugs used for clinical purpose.


All the prominent key players are investing in R&D and Merger & Acquisitions. The key players have a plenty of molecules as their future projects.

The report comprises of detailed discussion on the benefit of the pegylated antibody, its market growth, driving factors and challenges. Also, it puts light on the major key players and their contribution and development in the PEGylated Proteins Market.

PEGylated Drugs Market dynamics


Drivers


The main driving force behind the growth of the PEGylated Drugs Market are, the rising of prevalence diseases such as cancer, advancement of biologics sectors, and increasing pharmaceutical industries all across the globe. Additionally, the increasing number of chronic ailments and death rates because of cancer in Canada will provide a boost to the growth of the pegylated drugs on market.


Challenges


Although the benefits of pegylated drugs are many, but there are some backdrops available as well with it.  The side effects happening because of the drugs and the drug failure will make a restraining effect against the growth of the PEGylated Proteins Market during the forecast period.


Cumulative growth


PEGylated Drugs mainly have three benefits on the body.



  • Pharmacokinetics and pharmacodynamic properties Improvement


According to studies, the pharmacokinetic properties drastically changes in the body along with prolonging the plasma half-life; it also increases the release of drugs in the body and reduces the renal clearance rate.



  • Drug stability enhancement


A thicker hydration film forms on the surface preventing the precipitation and aggregation. The liposome stability is also increased by the modified linkage between lipid derivatives and PEG. Additionally, the flexible chain of PEG produces a hindrance effect which is steric protecting the modification from protease attack increasing the stability of the modification.



  • Drug distribution improvement in the body


The molecular weight of the drugs increases in the body after being modified by PEG that help reducing the glomerular filtration effects during systemic administration. Therefore, it increases the excretion in the urination. Moreover, PEGylated drugs are also responsible for improving the stability in the systemic circulation and prolongs retention time which is highly beneficial in the distribution of the drugs in one's body. Particularly it helps in accumulating macromolecular drugs in inflammatory sites and tumours. Therefore, it increases the span of treatment of the drugs in vivo.


 PEGylated Drugs Market Revenue, by Molecule, 2018 (% share)  PEGylated Drugs Market


Sources: MRFR Analysis


PEGylated Drugs Market Segmentation overview


Based on the PEGylated Drugs Market, it is segmented into-



  • Molecule

  • Indication

  • Region


PEGylated Drugs Market, By Molecule


Based on molecule, the PEGylated Proteins Market is further segmented into-



  • Protein

  • FAB’ Fragment

  • Enzyme

  • Aptamer


PEGylated Drugs Market, By Indication  


Based on indication, the PEGylated Proteins Market is further segmented into



  • Cancer

  • Gout

  • Hemophilia

  • Hepatitis


Cancer segment had 60% of the PEGylated Drugs Market share in 2017 owing to the increasing prevalence of diseases that demanded for a development in making effective drugs. The hepatitis segment is expected to grow at a CAGR of 12% over the forecast period. Moreover, the major key players focusing and developing the pegylated drugs using in chronic disease treatments will propel the growth of the market. For example, the market will be highly benefited with the launch of Pegasys drugs used for the treatment of Hepatitis C in adult patients.


 PEGylated Drugs Market Share, by Region, 2018 (%)      PEGylated Drugs Market 


Sources: MRFR Analysis


PEGylated Drugs Market, by Region


Based on region, the PEGylated Drugs Market is further segmented into-



  • North America

    • US

    • Canada



  • Latin America

  • Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe



  • Asia-Pacific

    • China

    • India

    • Japan

    • Australia & New Zealand

    • Southeast Asia

    • Rest of Asia-Pacific



  • Middle East & Africa

    • Middle East

    • Africa




 


PEGylated Drugs Market Regional analysis


Globally, the regional PEGylated Drugs Market is divided into Americas, Europe, Asia-Pacific and Middle East and Africa.


The American market is divided into North America and South America. The American market had a market share of 65.73% in 2018. U.S and Canada are the dominating region of the North American market. Canadian PEGylated Drugs Market is expected to witness a market growth of over 5.5% CAGR during the forecast period. The rising in the prevalence of chronic diseases such as cancer is driving the growth of the market. In 2017, more than 2lac people were diagnosed with cancer (as per the report of Canadian Cancer Society) which had emerged the demand of the pegylated drugs in the market.


Europe was the second-largest market in 2018. The European government supporting and investing in  reducing chronic diseases is the driving force behind the growth the regional market. The European region is further classified into Western Europe and Eastern Europe. Western Europe is also classified into the UK, Italy, France, Spain and the rest of the Western Europe. Italian PEGylated Drugs Market had a revenue of USD 218 million in 2017 and expected to witness a growth at a CAGR of 9% during the forecast period.


The Asia-Pacific region is further clssified into India, China, Japan, Australia, South Korea and the rest of Asia-Pacific. APAC holds the third-largest position in the regional PEGylated Drugs Market.


The Middle East and Africa is anticipated to witness a significant growth due to the rising application of pegylated drugs for treating the chronic diseases.


Competitive landscape


Few industry key players operating the market growth are investing in R&D in PEGylated technology is providing a huge boost in the growth of the PEGylated Drugs Market.   


Recent developments


In recent times, new  PEGylated drugs such as modified drugs using heterobifunctional PEG (X-PEG-Y) as a linker have been launched with the continuous deep research and developments.  It is also believed that in future, the continuous modification in the technology will produce more and more effective and better drugs.


Major key players


There are several major key players in the market. The players operating in the PEGylated Drugs Market are focusing on developing and launching new products and expanding their footprints in the global and larger markets. 



  • Horizon Therapeutics Plc • F. Hoffmann-La Roche Ltd. • Pfizer Inc. • Novo Nordisk A/S • UCB S.A. • Amgen, Inc. • AstraZeneca. • Merck & Co., Inc. • Takeda Pharmaceutical Company Limited • Bayer AG • Biogen • BioMarin Pharmaceutical Inc • Coherus BioSciences • Enzon • Leadiant Biosciences, Inc.


Report Overview


The report comprises of        



  • Market overview

  • Covid-19 impact

  • Market dynamics

  • Drivers

  • Challenges

  • Restrains

  • Opportunities

  • Technological analysis

  • Segmentation overview

  • Regional analysis

  • Competitive landscape

  • Recent developments

  • Major key players



Report Scope:

Report Attribute/Metric Details
  Market Size

  • 2025: USD 13,503.67 Million
  • 2027: Significant Value
  •   CAGR   5.53% (2018-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Molecule, Indication
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Bayer AG.
      Key Market Opportunities   The major companies are rigorously investing in R&D
      Key Market Drivers

  • Increase in the prevalence of chronic diseases such as cancer
  • Growing pharmaceutical industry
  • Advancements in the biologics sector


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The valuation of the global PEGylated drugs market is estimated to reach USD 13,503.67 MN. by 2025.

    The global PEGylated drugs market is projected to grow at approximately 5.53% CAGR during the forecast period (2019-2025).

    North America holds the largest share in the global PEGylated drugs market, followed by Europe and the Asia Pacific, respectively.

    F. Hoffmann-La Roche Ltd., Horizon Therapeutics Plc, Pfizer Inc., UCB S.A., Novo Nordisk A/S, Amgen, Inc., Merck & Co., Inc., AstraZeneca, Bayer AG, and Takeda Pharmaceutical Company Limited, are some of the major players operating in the PEGylated drugs market.